Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of April 22, 2024
Click Here to Manage Email Alerts
In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more.
Read the full coverage here:
FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis
Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes
Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis
New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure
Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA
References:
Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716.
Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531.
Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8.
Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.
Collapse
Click Here to Manage Email Alerts
